AIEOP acute lymphoblastic leukemia protocol

Chemotherapy treatment intensity (HDMTX exposure, intrathecal therapy doses, and cumulative dexamethasone dose) was not associated with any child self-reported or parent-reported behavioral symptoms o

Effect: null; RR 0.98 (95% CI 0.96-1.01) for HDMTX AUC on inattention; all p-values > 0.05 after FDR correction across all treatment-outcome combinations

Chemotherapy treatment intensity (HDMTX exposure, intrathecal therapy doses, and cumulative dexamethasone dose) was not associated with any child self-reported or parent-reported behavioral symptoms o

Effect: null; RR 0.98 (95% CI 0.96-1.01) for HDMTX AUC on inattention; all p-values > 0.05 after FDR correction across all treatment-outcome combinations

Chemotherapy treatment intensity (HDMTX exposure, intrathecal therapy doses, and cumulative dexamethasone dose) was not associated with any child self-reported or parent-reported behavioral symptoms o

Effect: null; RR 0.98 (95% CI 0.96-1.01) for HDMTX AUC on inattention; all p-values > 0.05 after FDR correction across all treatment-outcome combinations

Chemotherapy treatment intensity (HDMTX exposure, intrathecal therapy doses, and cumulative dexamethasone dose) was not associated with any child self-reported or parent-reported behavioral symptoms o

Effect: null; RR 0.98 (95% CI 0.96-1.01) for HDMTX AUC on inattention; all p-values > 0.05 after FDR correction across all treatment-outcome combinations

Chemotherapy treatment intensity (HDMTX exposure, intrathecal therapy doses, and cumulative dexamethasone dose) was not associated with any child self-reported or parent-reported behavioral symptoms o

Effect: null; RR 0.98 (95% CI 0.96-1.01) for HDMTX AUC on inattention; all p-values > 0.05 after FDR correction across all treatment-outcome combinations

Chemotherapy treatment intensity (HDMTX exposure, intrathecal therapy doses, and cumulative dexamethasone dose) was not associated with any child self-reported or parent-reported behavioral symptoms o

Effect: null; RR 0.98 (95% CI 0.96-1.01) for HDMTX AUC on inattention; all p-values > 0.05 after FDR correction across all treatment-outcome combinations

Chemotherapy treatment intensity (HDMTX exposure, intrathecal therapy doses, and cumulative dexamethasone dose) was not associated with any child self-reported or parent-reported behavioral symptoms o

Effect: null; RR 0.98 (95% CI 0.96-1.01) for HDMTX AUC on inattention; all p-values > 0.05 after FDR correction across all treatment-outcome combinations

Chemotherapy treatment intensity (HDMTX exposure, intrathecal therapy doses, and cumulative dexamethasone dose) was not associated with any child self-reported or parent-reported behavioral symptoms o

Effect: null; RR 0.98 (95% CI 0.96-1.01) for HDMTX AUC on inattention; all p-values > 0.05 after FDR correction across all treatment-outcome combinations

Chemotherapy treatment intensity (HDMTX exposure, intrathecal therapy doses, and cumulative dexamethasone dose) was not associated with any child self-reported or parent-reported behavioral symptoms o

Effect: null; RR 0.98 (95% CI 0.96-1.01) for HDMTX AUC on inattention; all p-values > 0.05 after FDR correction across all treatment-outcome combinations

Chemotherapy treatment intensity (HDMTX exposure, intrathecal therapy doses, and cumulative dexamethasone dose) was not associated with any child self-reported or parent-reported behavioral symptoms o

Effect: null; RR 0.98 (95% CI 0.96-1.01) for HDMTX AUC on inattention; all p-values > 0.05 after FDR correction across all treatment-outcome combinations

Chemotherapy treatment intensity (HDMTX exposure, intrathecal therapy doses, and cumulative dexamethasone dose) was not associated with any child self-reported or parent-reported behavioral symptoms o

Effect: null; RR 0.98 (95% CI 0.96-1.01) for HDMTX AUC on inattention; all p-values > 0.05 after FDR correction across all treatment-outcome combinations

Chemotherapy treatment intensity (HDMTX exposure, intrathecal therapy doses, and cumulative dexamethasone dose) was not associated with any child self-reported or parent-reported behavioral symptoms o

Effect: null; RR 0.98 (95% CI 0.96-1.01) for HDMTX AUC on inattention; all p-values > 0.05 after FDR correction across all treatment-outcome combinations

Chemotherapy treatment intensity (HDMTX exposure, intrathecal therapy doses, and cumulative dexamethasone dose) was not associated with any child self-reported or parent-reported behavioral symptoms o

Effect: null; RR 0.98 (95% CI 0.96-1.01) for HDMTX AUC on inattention; all p-values > 0.05 after FDR correction across all treatment-outcome combinations

Chemotherapy treatment intensity (HDMTX exposure, intrathecal therapy doses, and cumulative dexamethasone dose) was not associated with any child self-reported or parent-reported behavioral symptoms o

Effect: null; RR 0.98 (95% CI 0.96-1.01) for HDMTX AUC on inattention; all p-values > 0.05 after FDR correction across all treatment-outcome combinations

Chemotherapy treatment intensity (HDMTX exposure, intrathecal therapy doses, and cumulative dexamethasone dose) was not associated with any child self-reported or parent-reported behavioral symptoms o

Effect: null; RR 0.98 (95% CI 0.96-1.01) for HDMTX AUC on inattention; all p-values > 0.05 after FDR correction across all treatment-outcome combinations

Chemotherapy treatment intensity (HDMTX exposure, intrathecal therapy doses, and cumulative dexamethasone dose) was not associated with any child self-reported or parent-reported behavioral symptoms o

Effect: null; RR 0.98 (95% CI 0.96-1.01) for HDMTX AUC on inattention; all p-values > 0.05 after FDR correction across all treatment-outcome combinations

Chemotherapy treatment intensity (HDMTX exposure, intrathecal therapy doses, and cumulative dexamethasone dose) was not associated with any child self-reported or parent-reported behavioral symptoms o

Effect: null; RR 0.98 (95% CI 0.96-1.01) for HDMTX AUC on inattention; all p-values > 0.05 after FDR correction across all treatment-outcome combinations

Chemotherapy treatment intensity (HDMTX exposure, intrathecal therapy doses, and cumulative dexamethasone dose) was not associated with any child self-reported or parent-reported behavioral symptoms o

Effect: null; RR 0.98 (95% CI 0.96-1.01) for HDMTX AUC on inattention; all p-values > 0.05 after FDR correction across all treatment-outcome combinations

Chemotherapy treatment intensity (HDMTX exposure, intrathecal therapy doses, and cumulative dexamethasone dose) was not associated with any child self-reported or parent-reported behavioral symptoms o

Effect: null; RR 0.98 (95% CI 0.96-1.01) for HDMTX AUC on inattention; all p-values > 0.05 after FDR correction across all treatment-outcome combinations

Chemotherapy treatment intensity (HDMTX exposure, intrathecal therapy doses, and cumulative dexamethasone dose) was not associated with any child self-reported or parent-reported behavioral symptoms o

Effect: null; RR 0.98 (95% CI 0.96-1.01) for HDMTX AUC on inattention; all p-values > 0.05 after FDR correction across all treatment-outcome combinations

Chemotherapy treatment intensity (HDMTX exposure, intrathecal therapy doses, and cumulative dexamethasone dose) was not associated with any child self-reported or parent-reported behavioral symptoms o

Effect: null; RR 0.98 (95% CI 0.96-1.01) for HDMTX AUC on inattention; all p-values > 0.05 after FDR correction across all treatment-outcome combinations

Chemotherapy treatment intensity (HDMTX exposure, intrathecal therapy doses, and cumulative dexamethasone dose) was not associated with any child self-reported or parent-reported behavioral symptoms o

Effect: null; RR 0.98 (95% CI 0.96-1.01) for HDMTX AUC on inattention; all p-values > 0.05 after FDR correction across all treatment-outcome combinations

Chemotherapy treatment intensity (HDMTX exposure, intrathecal therapy doses, and cumulative dexamethasone dose) was not associated with any child self-reported or parent-reported behavioral symptoms o

Effect: null; RR 0.98 (95% CI 0.96-1.01) for HDMTX AUC on inattention; all p-values > 0.05 after FDR correction across all treatment-outcome combinations

Chemotherapy treatment intensity (HDMTX exposure, intrathecal therapy doses, and cumulative dexamethasone dose) was not associated with any child self-reported or parent-reported behavioral symptoms o

Effect: null; RR 0.98 (95% CI 0.96-1.01) for HDMTX AUC on inattention; all p-values > 0.05 after FDR correction across all treatment-outcome combinations

Chemotherapy treatment intensity (HDMTX exposure, intrathecal therapy doses, and cumulative dexamethasone dose) was not associated with any child self-reported or parent-reported behavioral symptoms o

Effect: null; RR 0.98 (95% CI 0.96-1.01) for HDMTX AUC on inattention; all p-values > 0.05 after FDR correction across all treatment-outcome combinations

Chemotherapy treatment intensity (HDMTX exposure, intrathecal therapy doses, and cumulative dexamethasone dose) was not associated with any child self-reported or parent-reported behavioral symptoms o

Effect: null; RR 0.98 (95% CI 0.96-1.01) for HDMTX AUC on inattention; all p-values > 0.05 after FDR correction across all treatment-outcome combinations

Chemotherapy treatment intensity (HDMTX exposure, intrathecal therapy doses, and cumulative dexamethasone dose) was not associated with any child self-reported or parent-reported behavioral symptoms o

Effect: null; RR 0.98 (95% CI 0.96-1.01) for HDMTX AUC on inattention; all p-values > 0.05 after FDR correction across all treatment-outcome combinations

Among ALL survivors who were 15 years or older at diagnosis, every 1000 units/m2 increase in asparaginase dose increased the odds of developing drug-induced diabetes by 12%.

Effect: decline; OR 1.12 per 1000 units/m2; CI: 95% CI 1.02-1.23

Among ALL survivors who were 15 years or older at diagnosis, every 1000 units/m2 increase in asparaginase dose increased the odds of developing drug-induced diabetes by 12%.

Effect: decline; OR 1.12 per 1000 units/m2; CI: 95% CI 1.02-1.23

Among ALL survivors who were 15 years or older at diagnosis, every 1000 units/m2 increase in asparaginase dose increased the odds of developing drug-induced diabetes by 12%.

Effect: decline; OR 1.12 per 1000 units/m2; CI: 95% CI 1.02-1.23

Among ALL survivors who were 15 years or older at diagnosis, every 1000 units/m2 increase in asparaginase dose increased the odds of developing drug-induced diabetes by 12%.

Effect: decline; OR 1.12 per 1000 units/m2; CI: 95% CI 1.02-1.23

Among ALL survivors who were 15 years or older at diagnosis, every 1000 units/m2 increase in asparaginase dose increased the odds of developing drug-induced diabetes by 12%.

Effect: decline; OR 1.12 per 1000 units/m2; CI: 95% CI 1.02-1.23

Among ALL survivors who were 15 years or older at diagnosis, every 1000 units/m2 increase in asparaginase dose increased the odds of developing drug-induced diabetes by 12%.

Effect: decline; OR 1.12 per 1000 units/m2; CI: 95% CI 1.02-1.23

Among ALL survivors who were 15 years or older at diagnosis, every 1000 units/m2 increase in asparaginase dose increased the odds of developing drug-induced diabetes by 12%.

Effect: decline; OR 1.12 per 1000 units/m2; CI: 95% CI 1.02-1.23

Among ALL survivors who were 15 years or older at diagnosis, every 1000 units/m2 increase in asparaginase dose increased the odds of developing drug-induced diabetes by 12%.

Effect: decline; OR 1.12 per 1000 units/m2; CI: 95% CI 1.02-1.23

Among ALL survivors who were 15 years or older at diagnosis, every 1000 units/m2 increase in asparaginase dose increased the odds of developing drug-induced diabetes by 12%.

Effect: decline; OR 1.12 per 1000 units/m2; CI: 95% CI 1.02-1.23

Among ALL survivors who were 15 years or older at diagnosis, every 1000 units/m2 increase in asparaginase dose increased the odds of developing drug-induced diabetes by 12%.

Effect: decline; OR 1.12 per 1000 units/m2; CI: 95% CI 1.02-1.23

Among ALL survivors who were 15 years or older at diagnosis, every 1000 units/m2 increase in asparaginase dose increased the odds of developing drug-induced diabetes by 12%.

Effect: decline; OR 1.12 per 1000 units/m2; CI: 95% CI 1.02-1.23

Among ALL survivors who were 15 years or older at diagnosis, every 1000 units/m2 increase in asparaginase dose increased the odds of developing drug-induced diabetes by 12%.

Effect: decline; OR 1.12 per 1000 units/m2; CI: 95% CI 1.02-1.23

Among ALL survivors who were 15 years or older at diagnosis, every 1000 units/m2 increase in asparaginase dose increased the odds of developing drug-induced diabetes by 12%.

Effect: decline; OR 1.12 per 1000 units/m2; CI: 95% CI 1.02-1.23

Among ALL survivors who were 15 years or older at diagnosis, every 1000 units/m2 increase in asparaginase dose increased the odds of developing drug-induced diabetes by 12%.

Effect: decline; OR 1.12 per 1000 units/m2; CI: 95% CI 1.02-1.23

Among ALL survivors who were 15 years or older at diagnosis, every 1000 units/m2 increase in asparaginase dose increased the odds of developing drug-induced diabetes by 12%.

Effect: decline; OR 1.12 per 1000 units/m2; CI: 95% CI 1.02-1.23

Among ALL survivors who were 15 years or older at diagnosis, every 1000 units/m2 increase in asparaginase dose increased the odds of developing drug-induced diabetes by 12%.

Effect: decline; OR 1.12 per 1000 units/m2; CI: 95% CI 1.02-1.23

Among ALL survivors who were 15 years or older at diagnosis, every 1000 units/m2 increase in asparaginase dose increased the odds of developing drug-induced diabetes by 12%.

Effect: decline; OR 1.12 per 1000 units/m2; CI: 95% CI 1.02-1.23

Among ALL survivors who were 15 years or older at diagnosis, every 1000 units/m2 increase in asparaginase dose increased the odds of developing drug-induced diabetes by 12%.

Effect: decline; OR 1.12 per 1000 units/m2; CI: 95% CI 1.02-1.23

Among ALL survivors who were 15 years or older at diagnosis, every 1000 units/m2 increase in asparaginase dose increased the odds of developing drug-induced diabetes by 12%.

Effect: decline; OR 1.12 per 1000 units/m2; CI: 95% CI 1.02-1.23

Among ALL survivors who were 15 years or older at diagnosis, every 1000 units/m2 increase in asparaginase dose increased the odds of developing drug-induced diabetes by 12%.

Effect: decline; OR 1.12 per 1000 units/m2; CI: 95% CI 1.02-1.23

Among ALL survivors who were 15 years or older at diagnosis, every 1000 units/m2 increase in asparaginase dose increased the odds of developing drug-induced diabetes by 12%.

Effect: decline; OR 1.12 per 1000 units/m2; CI: 95% CI 1.02-1.23

Among ALL survivors who were 15 years or older at diagnosis, every 1000 units/m2 increase in asparaginase dose increased the odds of developing drug-induced diabetes by 12%.

Effect: decline; OR 1.12 per 1000 units/m2; CI: 95% CI 1.02-1.23

Among ALL survivors who were 15 years or older at diagnosis, every 1000 units/m2 increase in asparaginase dose increased the odds of developing drug-induced diabetes by 12%.

Effect: decline; OR 1.12 per 1000 units/m2; CI: 95% CI 1.02-1.23